FDA approves Wegovy HD 7.2 mg, adding a sixth single-dose pen strength

The FDA approved Wegovy HD (semaglutide) injection 7.2 mg on March 19, 2026, a higher-dose version of the once-weekly obesity drug ^[1][3]. Novo Nordisk says the dose is for adults with obesity who have tolerated the 2.4 mg dosage for at least 4 weeks and for whom additional weight reduction is clinically indicated ^[1]. The company expects a US launch in April 2026 ^[4].

The approval came 54 days after filing and was the fourth granted under the FDA Commissioner's National Priority Voucher pilot program, which offers rolling review and faster communication for applications the agency considers national health priorities ^[3]. It is the first GLP-1 treatment approved under that program ^[4].

What the trials showed

Approval rests on the STEP UP program. STEP UP enrolled 1,407 adults with a BMI of 30 or higher and without diabetes, randomized 5:1:1 to semaglutide 7.2 mg, 2.4 mg, or placebo alongside lifestyle changes for 72 weeks ^[1]. Average baseline weight was 248 lb in the 7.2 mg and placebo groups and 257 lb in the 2.4 mg group ^[1].

If all patients had stayed on treatment, average weight loss was 20.7% with 7.2 mg, 17.5% with 2.4 mg, and 2.4% with placebo ^[1]. Counting everyone regardless of whether they stayed on treatment, Novo's US release reports 18.8% for 7.2 mg, 15.5% for 2.4 mg, and 3.9% for placebo ^[1]; the company's global release and a trade report list 18.7% for the 7.2 mg figure, a small discrepancy the sources do not explain ^[4][5]. About 31.2% of people on 7.2 mg lost 25% or more of their body weight, versus 15.3% on 2.4 mg and 0% on placebo ^[1]. Some 89% on 7.2 mg lost at least 5%, versus 38% on placebo ^[1].

A companion trial, STEP UP T2D, enrolled roughly 512 adults with obesity and type 2 diabetes and reported 14.1% mean weight loss under the adherence-based analysis and 13.2% regardless of adherence, with 21.3% losing 20% or more ^[4][5]. FDA said blood sugar lowering, measured by A1C, was similar at the higher and lower dosages in people with obesity and type 2 diabetes ^[3].

Side effects to know about

The most common adverse reactions with Wegovy HD were nausea, vomiting, dysesthesia, constipation, abdominal pain, fatigue, headache, dizziness, hair loss and flatulence ^[1]. Altered skin sensation — sensitive skin, hyperesthesia, dysesthesia, paresthesia — was reported by 22% of people on 7.2 mg, compared with 6% on 2.4 mg and 0.3% on placebo ^[1]. In STEP UP T2D, dysesthesia occurred in 18.9% on 7.2 mg versus 4.9% on 2.4 mg and 0% on placebo ^[5]. FDA said these reports generally resolved on their own or with a dose reduction, and that the agency is conducting further investigations into the reaction ^[3]. Wegovy keeps its boxed warning about thyroid C-cell tumors seen in rodents and is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2 ^[2][3].

Why it matters for patients

The practical change at the pharmacy counter is a sixth strength. The prescribing information now lists single-dose pens at 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg and 7.2 mg, alongside single-dose syringes and the multi-dose FlexTouch pen that delivers four 2.4 mg doses ^[2]. More strengths in circulation means more chances for a mix-up between a maintenance pen and the high-dose pen, and each strength carries its own Instructions for Use ^[2].

Eligibility is narrower than the headline suggests: the company frames 7.2 mg as a step up for people who have already tolerated 2.4 mg for at least 4 weeks ^[1]. Trade coverage describes it as an option for people whose weight loss on 2.4 mg was not enough ^[5]. What the higher dose costs, and whether insurers will cover it, is not yet known; Novo says coverage and savings details will come at launch ^[1].

What happens next

Novo says Wegovy HD will be available in April 2026 through more than 70,000 US pharmacies including CVS and Costco, select telehealth providers, NovoCare Pharmacy and GoodRx ^[1][4]. The 7.2 mg dose is already approved in the EU and UK, with decisions on the single-dose pen expected in the second half of 2026 ^[4]. FDA plans a public hearing in June on the voucher program ^[3].